{"preliminary_commentary":{"by_channel":{"podcast":2,"youtube":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CLL2-BZAG","nct_id":"NCT04515238","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cll2-bzag-nct04515238. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CLL2-BZAG","arms":[{"description":"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated\n\nInduction: 6 cycles (q 28d) of Obinutuzumab + Zanubrutinib + Venetoclax\n\nMaintenance: max. 8 cycles (q 84d) of Obinutuzumab + Zanubrutinib + Venetoclax\n\nMaintenance treatment will be continued until (whichever occurs first):\n\n* 12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity\n* maintenance cycle 8\n* progression of CLL or start of a subsequent therapy unacceptable toxicity","label":"BZAG","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02","type":"ESTIMATED"},"conditions":["Chronic Lymphoid Leukemia"],"enrollment":{"count":42,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Bendamustine","otherNames":["Treanda","Bendeka"],"type":"DRUG"},{"name":"Obinutuzumab","otherNames":["GA101","Gazyvaro"],"type":"BIOLOGICAL"},{"name":"Zanubrutinib","otherNames":["BGB-3111"],"type":"BIOLOGICAL"},{"name":"Venetoclax","otherNames":["ABT-199","Venclyxto"],"type":"BIOLOGICAL"}],"last_update":"2026-08-20","lead_sponsor":"German CLL Study Group","official_title":"A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG Protocol)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Negativity rate of minimal residual disease (MRD) in peripheral blood (PB) measured by multi-color flow cytometry","timeFrame":"At final restaging (RE): 12 weeks after the start of the last induction cycle"}],"references":[{"citation":"Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring J, Hebart H, Schottker B, Illert AL, Graeven U, Stoltefuss A, Heinrich B, Eckert R, Fink A, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Bruggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. Blood. 2025 Mar 20;145(12):1282-1292. doi: 10.1182/blood.2024026685.","pmid":"39883943","type":"DERIVED"}],"start_date":{"date":"2020-10-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL","url":"https://clinicaltrials.gov/study/NCT04515238"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cll2-bzag-nct04515238"}